Mediwound, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $30.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Okunewitch’s rating is based on several promising developments within MediWound’s pipeline and financial outlook. The company has reported a revenue of $5.7 million for the second quarter of 2025, with sufficient cash reserves projected to last into 2027, providing a stable financial foundation. Additionally, MediWound’s guidance for 2025 anticipates revenue of at least $24 million, indicating growth potential.
Furthermore, the ongoing Phase 3 VALUE study for EscharEx, targeting venous leg ulcers, is progressing with an interim analysis expected in mid-2026. EscharEx is positioned as a disruptive technology in the chronic wound care market, with a significant market opportunity estimated at $2.5 billion. The planned head-to-head study against the current market leader, Santyl, and the upcoming Phase 2/3 study for diabetic foot ulcers, underscore the potential for EscharEx to capture a substantial market share. These factors collectively contribute to Okunewitch’s Buy rating for MediWound.